CY1106504T1 - Υβριδιακες πρωτεϊνες του τοξοειδους του τετανου που μετακινουνται παλινδρομικα και διασυναπτικα στο κνς - Google Patents
Υβριδιακες πρωτεϊνες του τοξοειδους του τετανου που μετακινουνται παλινδρομικα και διασυναπτικα στο κνςInfo
- Publication number
- CY1106504T1 CY1106504T1 CY20071100505T CY071100505T CY1106504T1 CY 1106504 T1 CY1106504 T1 CY 1106504T1 CY 20071100505 T CY20071100505 T CY 20071100505T CY 071100505 T CY071100505 T CY 071100505T CY 1106504 T1 CY1106504 T1 CY 1106504T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ttc
- neurons
- palindromically
- transsynaptically
- cns
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 229960000814 tetanus toxoid Drugs 0.000 title 1
- 210000002569 neuron Anatomy 0.000 abstract 4
- 210000000225 synapse Anatomy 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108010055044 Tetanus Toxin Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 abstract 1
- 108010005774 beta-Galactosidase Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000008827 biological function Effects 0.000 abstract 1
- 210000000133 brain stem Anatomy 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000010255 intramuscular injection Methods 0.000 abstract 1
- 239000007927 intramuscular injection Substances 0.000 abstract 1
- 210000002161 motor neuron Anatomy 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000002797 proteolythic effect Effects 0.000 abstract 1
- 229940118376 tetanus toxin Drugs 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 230000003363 transsynaptic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
To μη τοξικό πρωτεολυτικό τμήμα C της τοξίνης του τετάνου (TTC πεπτίδιο) έχει την ίδια ικανότητα πρόσδεσης στα νευρικά κύτταρα και μεταφέρεται παλινδρομικά μέσω μίας σύναψης όμοια με την ενδογενή τοξίνη. Μία υβριδιακή πρωτεΐνη που κωδικοποιείται από την γονιδιακή σύντηξη lacZ- TTC διατηρεί τις βιολογικές λειτουργίες και των δύο πρωτεϊνών in vivo δηλ., την παλίνδρομη διασυναπτική μεταφορά του τμήματος TTC και την ενζυματική δραστικότητα β-gal. Μετά από ενδομυϊκή ένεση, η ενζυματική δραστικότητα μπορεί να ανιχνευθεί στους κινητικούς νευρώνες και στους συνδεδεμένους νευρώνες των περιοχών του στελέχους του εγκεφάλου. Η στρατηγική αυτή είναι χρήσιμη για την διανομή μιας βιολογικής δραστικότητας στους νευρώνες από την περιφέρεια προς το κεντρικό νευρικό σύστημα. Μία τέτοιου τύπου υβριδιακή πρωτεΐνη μπορεί επίσης να χρησιμοποιηθεί για την χαρτογράφηση συνοπτικών συνδέσεων μεταξύ νευρικών κυττάρων.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5561597P | 1997-08-14 | 1997-08-14 | |
US6523697P | 1997-11-13 | 1997-11-13 | |
PCT/EP1998/005113 WO1999009057A2 (en) | 1997-08-14 | 1998-08-12 | Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the cns |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106504T1 true CY1106504T1 (el) | 2012-01-25 |
Family
ID=26734425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100505T CY1106504T1 (el) | 1997-08-14 | 2007-04-12 | Υβριδιακες πρωτεϊνες του τοξοειδους του τετανου που μετακινουνται παλινδρομικα και διασυναπτικα στο κνς |
Country Status (9)
Country | Link |
---|---|
US (4) | US7435792B2 (el) |
EP (2) | EP1049712B1 (el) |
AT (1) | ATE352558T1 (el) |
CY (1) | CY1106504T1 (el) |
DE (1) | DE69836982T2 (el) |
DK (1) | DK1049712T3 (el) |
ES (1) | ES2281135T3 (el) |
PT (1) | PT1049712E (el) |
WO (1) | WO1999009057A2 (el) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995016774A1 (en) * | 1993-12-17 | 1995-06-22 | Spinal Cord Society | Method for inducing dna synthesis in neurons |
DE69836982T2 (de) * | 1997-08-14 | 2007-10-31 | Institut Pasteur | Hybride Tetanustoxinproteine die retrograd und transsynaptisch ins ZNS migrieren |
US7923015B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | Methods for direct visualization of active synapses |
US7923216B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
US7368532B2 (en) | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
ES2216996T3 (es) * | 1999-12-02 | 2004-11-01 | Health Protection Agency | Construcciones para suministrar agentes terapeuticos a celulas neuronales. |
WO2004021992A2 (en) * | 2002-09-06 | 2004-03-18 | The General Hospital Corporation | Delivery of therapeutics to the brain and spinal cord |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
WO2006070290A2 (en) * | 2004-06-23 | 2006-07-06 | Ferguson Ian A | Agents and methods for early diagnosis and monitoring of alzheimer's disease and other neurological disorders |
KR101667623B1 (ko) | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
CA2656104A1 (en) * | 2006-06-30 | 2008-01-10 | Board Of Regents, The University Of Texas System | Tetanus toxin fragment c based imaging agents and methods, and confocal microscopy dataset processes |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
ES2332628B1 (es) * | 2007-10-05 | 2011-01-24 | Universidad De Zaragoza | Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento. |
US8173768B2 (en) * | 2009-07-13 | 2012-05-08 | Centre National De La Recherche Scientifique | Peptides having antimicrobial and neurotrophic activity and uses thereof |
MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
WO2011143557A2 (en) | 2010-05-14 | 2011-11-17 | The Children's Hospital Of Philadelphia | Humanized ttc and methods of use thereof |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
EP3164149A1 (en) | 2014-07-02 | 2017-05-10 | Spherium Biomed S.L. | Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc) |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2470773B1 (el) * | 1979-11-28 | 1983-01-28 | Pasteur Institut | |
CA1178949A (en) | 1979-11-28 | 1984-12-04 | Bernard Bizzini | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its applications |
FR2498192A2 (fr) * | 1981-01-22 | 1982-07-23 | Pasteur Institut | Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications |
US4594336A (en) * | 1982-09-28 | 1986-06-10 | Institut Pasteur | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application |
US5004683A (en) * | 1986-07-31 | 1991-04-02 | The Research Foundation Of State University Of New York | Means for detecting and analyzing neuroanatomy |
US5728383A (en) | 1987-10-05 | 1998-03-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatment of tumors of the central nervous system with immunotoxins |
US5650148A (en) * | 1988-12-15 | 1997-07-22 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system |
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
GB8914122D0 (en) * | 1989-06-20 | 1989-08-09 | Wellcome Found | Polypeptide expression |
US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US5766948A (en) * | 1993-01-06 | 1998-06-16 | The Regents Of The University Of California | Method for production of neuroblasts |
CA2168459C (en) * | 1993-07-30 | 2002-10-01 | Mohammed Anjam Khan | Fusion proteins containing the c-terminal of tetanus toxin linked to a heterologous protein |
US6551618B2 (en) * | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
US5728399A (en) * | 1994-06-29 | 1998-03-17 | University Of Conn. | Use of a bacterial component to enhance targeted delivery of polynucleotides to cells |
US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
US5580839A (en) * | 1994-09-30 | 1996-12-03 | University Of Kentucky Research Foundation | Binary ferrihydrite catalysts |
US5986054A (en) * | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
US5780024A (en) * | 1995-06-23 | 1998-07-14 | The General Hospital Corp. | Superoxide dismutase/tetanus toxin fragment C hybrid protein |
ATE398459T1 (de) * | 1996-04-26 | 2008-07-15 | Univ Ottawa | Verwendung von naip oder iap für die behandlung und vorbeugung von neuronalen erkrankungen |
US5738383A (en) * | 1996-11-20 | 1998-04-14 | Kobel, Inc. | Label assembly with patterned adhesive bands |
US7923015B2 (en) * | 1997-08-14 | 2011-04-12 | Institut Pasteur | Methods for direct visualization of active synapses |
DE69836982T2 (de) * | 1997-08-14 | 2007-10-31 | Institut Pasteur | Hybride Tetanustoxinproteine die retrograd und transsynaptisch ins ZNS migrieren |
US7923216B2 (en) * | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
US20100081197A1 (en) * | 1997-08-14 | 2010-04-01 | Sylvie Roux | In vivo modulation of neuronal transport |
US20030083299A1 (en) * | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
US20030031702A1 (en) * | 2001-07-27 | 2003-02-13 | Mazur Leonard L. | Safer teratogenic pharmaceuticals |
US20070092449A1 (en) * | 2005-04-05 | 2007-04-26 | Rafael Vazquez-Martinez | Methods for direct visualization of active synapses |
-
1998
- 1998-08-12 DE DE69836982T patent/DE69836982T2/de not_active Expired - Lifetime
- 1998-08-12 ES ES98945222T patent/ES2281135T3/es not_active Expired - Lifetime
- 1998-08-12 PT PT98945222T patent/PT1049712E/pt unknown
- 1998-08-12 EP EP98945222A patent/EP1049712B1/en not_active Expired - Lifetime
- 1998-08-12 DK DK98945222T patent/DK1049712T3/da active
- 1998-08-12 AT AT98945222T patent/ATE352558T1/de active
- 1998-08-12 EP EP06004471A patent/EP1681300A1/en not_active Withdrawn
- 1998-08-12 WO PCT/EP1998/005113 patent/WO1999009057A2/en active IP Right Grant
-
2001
- 2001-03-26 US US09/816,467 patent/US7435792B2/en not_active Expired - Fee Related
-
2007
- 2007-04-12 CY CY20071100505T patent/CY1106504T1/el unknown
- 2007-06-21 US US11/812,812 patent/US20090226468A1/en not_active Abandoned
-
2008
- 2008-06-26 US US12/213,982 patent/US20100239534A1/en not_active Abandoned
-
2010
- 2010-07-07 US US12/831,976 patent/US20110002914A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030004121A1 (en) | 2003-01-02 |
DE69836982D1 (de) | 2007-03-15 |
WO1999009057A3 (en) | 1999-07-08 |
PT1049712E (pt) | 2007-04-30 |
US7435792B2 (en) | 2008-10-14 |
US20100239534A1 (en) | 2010-09-23 |
EP1681300A1 (en) | 2006-07-19 |
EP1049712A2 (en) | 2000-11-08 |
US20110002914A1 (en) | 2011-01-06 |
US20090226468A1 (en) | 2009-09-10 |
ATE352558T1 (de) | 2007-02-15 |
DE69836982T2 (de) | 2007-10-31 |
ES2281135T3 (es) | 2007-09-16 |
WO1999009057A2 (en) | 1999-02-25 |
DK1049712T3 (da) | 2007-05-29 |
EP1049712B1 (en) | 2007-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106504T1 (el) | Υβριδιακες πρωτεϊνες του τοξοειδους του τετανου που μετακινουνται παλινδρομικα και διασυναπτικα στο κνς | |
DE69521331T2 (de) | Nukleinsäure-einbringungssystem | |
TR200101484T2 (tr) | Alzheimer hastalığı sekretazı | |
AR001731A1 (es) | Nueva celulasa método para producirla composición que la contiene vector que comprende al adn que lacodifica celula huesped método de aplicación | |
ATE345682T1 (de) | In vitro verfahren zum einbringen von nukleinsäuren in eine zelle | |
DE60132075D1 (de) | Wnt-1 verwandte polypeptide und dafür kodierende nukleinsäuren | |
DE69430818T2 (de) | Pns-dns-pns-chimäre makromoleküle | |
PT941352E (pt) | Milhoramentos em, ou relacionados com, o conteudo de amido em plantas. | |
DE69826452D1 (de) | Stellenspezifische proteinmodifizierung | |
EP0957926A4 (en) | OLIGONUCLEOTIDE COMPOSITION AND METHOD FOR REGULATING THE PROTEIN B7 EXPRESSION | |
WO1999025878A3 (en) | Methods for modulating and identifying cellular senescence | |
Yokoyama et al. | Isolation of prokaryotic V0V1-ATPase from a thermophilic eubacterium Thermus thermophilus. | |
NZ527971A (en) | Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon | |
DE60036555D1 (de) | Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter | |
DE69837265D1 (de) | Polypeptide zur regenerierung des nervensystems | |
Medda et al. | Identity of esterase-22 and egasyn, the protein which complexes with microsomal β-glucuronidase | |
CO4480058A1 (es) | Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa | |
DE69633506D1 (de) | Transepithelialer transport von molekularspezien | |
WO1997020579A3 (en) | Novel compounds and use | |
WO1998005760A3 (en) | Phosphate starvation-inducible proteins | |
GR1001480B (el) | Ενζυμικά σκευάσματα περιέχοντα παπαϊνη ή χυμο?ρυψίνη και μέ?οδοι μόνιμης ενζυμικής αποτρίχωσης. | |
EP0888374A4 (en) | NUCLEIC ACID LIGANDS WITH HIGH AFFINITY FOR THE PROTEINS OF THE COMPLEMENT SYSTEM | |
Hermier et al. | Action of protease I of Escherichia coli on RNA polymerase of same origin | |
CO4440441A1 (es) | Enzima dextranasa, metodo para su produccion y adn que la codifica | |
Nakagawa et al. | Fragmentation of Penicillin-binding Protein-1Bs of Escherichia coli by Proteolytic Enzymes: A Preliminary Study on the Location of the Penicillin-binding Site on the Bifunctional Peptidoglycan Synthetase Protein |